David Dai
Stock Analyst at UBS
(0.53)
# 3,973
Out of 4,905 analysts
26
Total ratings
22.73%
Success rate
-23.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $37 → $35 | $9.46 | +269.98% | 2 | Jul 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $11.21 | +131.94% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $26.20 | +14.50% | 1 | Jul 1, 2025 | |
| BPMC Blueprint Medicines | Maintains: Neutral | $88 → $129 | $129.46 | -0.36% | 2 | Jun 5, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.23 | -10.31% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $7.53 | +218.73% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $83.31 | +20.04% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $6.36 | +120.13% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $36.32 | -33.92% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $4.20 | +376.19% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $63.26 | +13.82% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $26.40 | +161.36% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $21.59 | +131.59% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $26.75 | +124.30% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.76 | +3,586.64% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $24.42 | +63.80% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.48 | +2,602.70% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.91 | +2,517.80% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $33.92 | +53.30% | 1 | Mar 17, 2020 |
Syndax Pharmaceuticals
Jul 15, 2025
Maintains: Buy
Price Target: $37 → $35
Current: $9.46
Upside: +269.98%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $11.21
Upside: +131.94%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $26.20
Upside: +14.50%
Blueprint Medicines
Jun 5, 2025
Maintains: Neutral
Price Target: $88 → $129
Current: $129.46
Upside: -0.36%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.23
Upside: -10.31%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $7.53
Upside: +218.73%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $83.31
Upside: +20.04%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $6.36
Upside: +120.13%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $36.32
Upside: -33.92%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $4.20
Upside: +376.19%
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $63.26
Upside: +13.82%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $26.40
Upside: +161.36%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $21.59
Upside: +131.59%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $26.75
Upside: +124.30%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.76
Upside: +3,586.64%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $24.42
Upside: +63.80%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.48
Upside: +2,602.70%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.91
Upside: +2,517.80%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $33.92
Upside: +53.30%